Influence of baseline characteristics and stratification level of patients living with HIV on pharmaceutical interventions developed according to the Capacity-Motivation-Opportunity methodology

• Published in: European journal of hospital pharmacy. Science and practice p. ejhpharm-2023-003780
• Main Authors: Cárdaba García, María Elena, Pedraza Cezón, Luis Antonio, Andrés Rosado, Ana, Contreras Macías, Enrique, Lorenzo Giménez, Susana
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 06.07.2023
• Subjects: Disease control; Drug therapy; Education; Geriatrics; HIV; Hospitals; Human immunodeficiency virus; Infections; Motivation; Normal distribution; Patients; Pharmaceuticals; Pharmacists; Polypharmacy; Population; Sociodemographics; Taxonomy; Variables; VIROLOGY; Education, Pharmacy, Continuing; HIV; EDUCATION, PHARMACY; PHARMACY SERVICE, HOSPITAL
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2023-003780

In recent years the therapeutic approach to patients with HIV has gone from being multidisciplinary to multidimensional, being vital to know the different aspects that define patients in order to outline the best care interventions for each patient. The aim of this study was to determine the influence of the individual characteristics (demographic and clinical, pharmacotherapeutic and HIV infection control data) of patients with HIV being followed up using the Capacity-Motivation-Opportunity methodology on the pharmaceutical interventions performed. A single-centre prospective observational study was conducted between February 2019 and January 2020. Patients with HIV aged ≥18 years on antiretroviral treatment and who were receiving pharmaceutical care based on the Capacity-Motivation-Opportunity methodology were included. Demographic, clinical and pharmaceutical variables and HIV infection control data were registered at baseline. To identify the independent variables associated with pharmaceutical interventions, a univariate logistic regression was performed. Sixty-five patients were included in the study. A total of 129 pharmaceutical care consultations were performed and 909 pharmaceutical interventions were carried out: 503/909 (55.3%) capacity interventions, 381/909 (41.9%) motivation interventions, 25/909 (2.8%) opportunity interventions. The educational level had a significant influence on the opportunity (p=0.025) and transversal training interventions performed (p=0.001). A relationship was found between the antiretroviral therapy received and the development of safety interventions (p=0.037). The presence of polypharmacy significantly influenced concomitant review and validation (p=0.030) and motivation interventions (p=0.041). Adherence of ≥95% had a significant influence on the motivation interventions carried out (p=0.038). Stratification significantly influenced adherence interventions (p=0.033). The sex and age of the patients, as well as their toxic habits, presence of comorbidities, CD4+ cell count and HIV viral load, did not significantly influence the pharmaceutical interventions performed (p>0.05). Our study has elucidated the pharmaceutical interventions carried out in a pharmaceutical care consultation for patients with HIV based on the Capacity-Motivation-Opportunity model and ascertained the individual characteristics (demographic and clinical, pharmacotherapeutic and HIV infection control data) that may have conditioned them.